tbuckley/cabot-search huggingface dataset:
TEMPORAL MORTALITY TRENDS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, STROKE, AND PULMONARY EMBOLISM IN THE UNITED STATES
Authors: Mohamed Zghouzi, Supriya Shore, Hunter Mwansa, Syed Hyder, Neil Kamdar, Victor Moles, Geoffrey D. Barnes, James B. Froehlich, Vallerie V. McLaughlin, Timir K. Paul, Brahmajee K. Nallamothu, Vikas Aggarwal
Journal: Journal of the American College of Cardiology (2023)
A MACHINE LEARNING-GUIDED APPROACH FOR ADAPTIVE TRIAL ENRICHMENT AND ACCELERATION OF CARDIOVASCULAR OUTCOME TRIALS: INSIGHTS FROM THE SPRINT AND ACCORD-BP TRIALS
Authors: Evangelos K. Oikonomou, Erica Sarah Spatz, Joseph S. Ross, Marc Suchard, Harlan M. Krumholz, Rohan Khera
Journal: Journal of the American College of Cardiology (2023)
ROUTINE USE OF CEREBRAL EMBOLIC PROTECTION DEVICE DURING TRANSCATHETER AORTIC VALVE REPLACEMENT: WHAT DOES THE DATA SUPPORT? AN UPDATED META-ANALYSIS
Authors: Issam Atallah, Debapria Das, Tarek Nafee, Chien-Jung Lin, Kishore J. Harjai, Ammar Nasir, Michael Forsberg, Deana Mikhalkova, Philip L. Mar, Kartik Mani, Sridhar Sampath-Kumar, Sunil Prasad, Anne Cahill, Divya Ratan Verma
Journal: Journal of the American College of Cardiology (2023)
NON-ALCOHOLIC FATTY LIVER DISEASE PREDICTS ACUTE KIDNEY INJURY READMISSIONS IN HEART FAILURE PATIENTS: A NATIONWIDE ANALYSIS
Authors: Ahmed M. Maraey, Ahmed Elzanaty, Hadeer Rafat Elsharnoby, Ahmed Hashim, Mahmoud Khalil, Ahmed Younes, Mahmoud Salem, Helmy Siragy
Journal: Journal of the American College of Cardiology (2023)
DECLINING SERIAL B-TYPE NATRIURETIC PEPTIDE LEVEL PREDICTS SUCCESSFUL WEANING OF VASOACTIVE THERAPY IN PEDIATRIC ACUTE DECOMPENSATED HEART FAILURE
Authors: Karla Loss, Jennifer Ann-Li Su, Jondavid Menteer, Molly Weisert, Robert E. Shaddy, Paul F. Kantor
Journal: Journal of the American College of Cardiology (2023)
RECONSIDERING PULMONARY HYPERTENSION AS CONTRAINDICATION TO TRANSPLANT: A CASE OF RESTRICTIVE CARDIOMYOPATHY AND STIFF LEFT ATRIUM
Authors: Claire Z. Scott, Jamal Hussain Mahar, Laura Lelenwa, Andrew B. Civitello, Raymond Bietry, Alexis E. Shafii, Ajith Nair
Journal: Journal of the American College of Cardiology (2023)
CORONARY ARTERY BYPASS GRAFT SURGERY OUTCOMES IN PATIENTS WITH AND WITHOUTCOVID-19 DURING THE PANDEMIC FIRST WAVE
Authors: Bruna Scarpa Matuck, Henrique Pinesi, Eduardo Martins, Cibele Larrosa Garzillo, Marcos Pita Lottenberg, Joao A.C. Lima, Alexandre Segre, Desiderio Favarato, Eduardo Gomes Lima, Fabiana Hanna Rached, Fabio Grunspun Pitta, Luiz Augusto Lisboa, Fabio Biscegli Jatene, Roberto Kalil-Filho, Carlos V. Serrano
Journal: Journal of the American College of Cardiology (2023)
RELATIONSHIP BETWEEN EARLY DIASTOLIC STRAIN RATE AND CORONARY ARTERY CALCIUM SCORE IN PATIENTS SUSPECTED OF CORONARY ARTERY DISEASE
Authors: Mats H⊘jbjerg Lassen, Tor Biering-Sorensen, Philip Brainin, Jan Bech, sune a. pedersen, Thomas Fritz Hansen, Flemming Javier Olsen
Journal: Journal of the American College of Cardiology (2023)
Interleukin‐37 promotes DMBA/TPA skin cancer through SIGIRR‐mediated inhibition of glycolysis in CD103<sup>+</sup>DC cells
Authors: Fan‐lian Zeng, Xiao‐yan Wang, Ya‐wen Hu, Zhen Wang, Ya Li, Jing Hu, Jia‐dong Yu, Pei Zhou, Xiu Teng, Hong Zhou, Hua‐ping Zheng, Fu‐lei Zhao, Lin‐na Gu, Cheng‐cheng Yue, Shu‐wen Chen, Juan Cheng, Yan Hao, Qi‐xiang Zhao, Chen Zhang, Song Zou, Zhong‐lan Hu, Xiao‐qiong Wei, Xiao Liu, Guo‐lin Li, Nong‐yu Huang, Wen‐ling Wu, Yi‐fan Zhou, Wei Li, Kaijun Cui, Jiong Li
Journal: MedComm (2023)

Abstract Interleukin 37 (IL‐37), a member of the IL‐1 family, is considered a suppressor of innate and adaptive immunity and, hence is a regulator of tumor immunity. However, the specific molecular mechanism and role of IL‐37 in skin cancer remain unclear. Here, we report that IL‐37b‐transgenic mice (IL‐37tg) treated with the carcinogenic 7,12‐dimethylbenzoanthracene (DMBA)/12‐o‐tetradecylphorbol‐13‐acetate (TPA) exhibited enhanced skin cancer and increased tumor burden in the skin by inhibiting the function of CD103 + dendritic cells (DCs). Notably, IL‐37 induced rapid phosphorylation of adenosine 5‘‐monophosphate (AMP)‐activated protein kinase (AMPK), and via single immunoglobulin IL‐1‐related receptor (SIGIRR), inhibited the long‐term Akt activation. Specifically, by affecting the SIGIRR‐AMPK‐Akt signaling axis, which is related to the regulation of glycolysis in CD103 + DCs, IL‐37 inhibited their anti‐tumor function. Our results show that a marked correlation between the CD103 + DC signature (IRF8, FMS‐like tyrosine kinase 3 ligand, CLEC9A, CLNK, XCR1, BATF3, and ZBTB46) and chemokines C‐X‐C motif chemokine ligand 9, CXCL10, and CD8A in a mouse model with DMBA/TPA‐induced skin cancer. In a word, our results highlight that IL‐37 as an inhibitor of tumor immune surveillance through modulating CD103 + DCs and establishing an important link between metabolism and immunity as a therapeutic target for skin cancer.
Applications and prospects of cryo-EM in drug discovery
Authors: Kong-Fu Zhu, Chuang Yuan, Yong-Ming Du, Kai-Lei Sun, Xiao-Kang Zhang, Horst Vogel, Xu-Dong Jia, Yuan-Zhu Gao, Qin-Fen Zhang, Da-Ping Wang, Hua-Wei Zhang
Journal: Military Medical Research (2023)

Abstract Drug discovery is a crucial part of human healthcare and has dramatically benefited human lifespan and life quality in recent centuries, however, it is usually time- and effort-consuming. Structural biology has been demonstrated as a powerful tool to accelerate drug development. Among different techniques, cryo-electron microscopy (cryo-EM) is emerging as the mainstream of structure determination of biomacromolecules in the past decade and has received increasing attention from the pharmaceutical industry. Although cryo-EM still has limitations in resolution, speed and throughput, a growing number of innovative drugs are being developed with the help of cryo-EM. Here, we aim to provide an overview of how cryo-EM techniques are applied to facilitate drug discovery. The development and typical workflow of cryo-EM technique will be briefly introduced, followed by its specific applications in structure-based drug design, fragment-based drug discovery, proteolysis targeting chimeras, antibody drug development and drug repurposing. Besides cryo-EM, drug discovery innovation usually involves other state-of-the-art techniques such as artificial intelligence (AI), which is increasingly active in diverse areas. The combination of cryo-EM and AI provides an opportunity to minimize limitations of cryo-EM such as automation, throughput and interpretation of medium-resolution maps, and tends to be the new direction of future development of cryo-EM. The rapid development of cryo-EM will make it as an indispensable part of modern drug discovery.
Self-assembled nanoformulations of paclitaxel for enhanced cancer theranostics
Authors: Qing Pei, Bowen Jiang, Dengyuan Hao, Zhigang Xie
Journal: Acta Pharmaceutica Sinica B (2023)

Chemotherapy has occupied the critical position in cancer therapy, especially towards the post-operative, advanced, recurrent, and metastatic tumors. Paclitaxel (PTX)-based formulations have been widely used in clinical practice, while the therapeutic effect is far from satisfied due to off-target toxicity and drug resistance. The caseless multi-components make the preparation technology complicated and aggravate the concerns with the excipients-associated toxicity. The self-assembled PTX nanoparticles possess a high drug content and could incorporate various functional molecules for enhancing the therapeutic index. In this work, we summarize the self-assembly strategy for diverse nanodrugs of PTX. Then, the advancement of nanodrugs for tumor therapy, especially emphasis on mono-chemotherapy, combinational therapy, and theranostics, have been outlined. Finally, the challenges and potential improvements have been briefly spotlighted.
Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial
Authors: Niklas Dyrby Johansen, Muthiah Vaduganathan, Ankeet S Bhatt, Simin Gharib Lee, Daniel Modin, Brian L Claggett, Erica L Dueger, Sandrine I Samson, Matthew M Loiacono, Lars Køber, Scott D Solomon, Pradeesh Sivapalan, Jens Ulrik Stæhr Jensen, Cyril Jean-Marie Martel, Palle Valentiner-Branth, Tyra Grove Krause, Tor Biering-Sørensen
Journal: The Lancet (2023)
Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation
Authors: Gregg W. Stone, William T. Abraham, JoAnn Lindenfeld, Saibal Kar, Paul A. Grayburn, D. Scott Lim, Jacob M. Mishell, Brian Whisenant, Michael Rinaldi, Samir R. Kapadia, Vivek Rajagopal, Ian J. Sarembock, Andreas Brieke, Steven O. Marx, David J. Cohen, Federico M. Asch, Michael J. Mack
Journal: New England Journal of Medicine (2023)

Data from a 5-year follow-up of outcomes after transcatheter edge-to-edge repair of severe mitral regurgitation, as compared with outcomes after maximal doses of guideline-directed medical therapy alone, in patients with heart failure are now available.We randomly assigned patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline-directed medical therapy to undergo transcatheter edge-to-edge repair plus receive medical therapy (device group) or to receive medical therapy alone (control group) at 78 sites in the United States and Canada. The primary effectiveness end point was all hospitalizations for heart failure through 2 years of follow-up. The annualized rate of all hospitalizations for heart failure, all-cause mortality, the risk of death or hospitalization for heart failure, and safety, among other outcomes, were assessed through 5 years.Of the 614 patients enrolled in the trial, 302 were assigned to the device group and 312 to the control group. The annualized rate of hospitalization for heart failure through 5 years was 33.1% per year in the device group and 57.2% per year in the control group (hazard ratio, 0.53; 95% confidence interval [CI], 0.41 to 0.68). All-cause mortality through 5 years was 57.3% in the device group and 67.2% in the control group (hazard ratio, 0.72; 95% CI, 0.58 to 0.89). Death or hospitalization for heart failure within 5 years occurred in 73.6% of the patients in the device group and in 91.5% of those in the control group (hazard ratio, 0.53; 95% CI, 0.44 to 0.64). Device-specific safety events within 5 years occurred in 4 of 293 treated patients (1.4%), with all the events occurring within 30 days after the procedure.Among patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite guideline-directed medical therapy, transcatheter edge-to-edge repair of the mitral valve was safe and led to a lower rate of hospitalization for heart failure and lower all-cause mortality through 5 years of follow-up than medical therapy alone. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079.).
Intravascular Imaging–Guided or Angiography-Guided Complex PCI
Authors: Joo Myung Lee, Ki Hong Choi, Young Bin Song, Jong-Young Lee, Seung-Jae Lee, Sang Yeub Lee, Sang Min Kim, Kyeong Ho Yun, Jae Young Cho, Chan Joon Kim, Hyo-Suk Ahn, Chang-Wook Nam, Hyuck-Jun Yoon, Yong Hwan Park, Wang Soo Lee, Jin-Ok Jeong, Pil Sang Song, Joon-Hyung Doh, Sang-Ho Jo, Chang-Hwan Yoon, Min Gyu Kang, Jin-Sin Koh, Kwan Yong Lee, Young-Hyo Lim, Yun-Hyeong Cho, Jin-Man Cho, Woo Jin Jang, Kook-Jin Chun, David Hong, Taek Kyu Park, Jeong Hoon Yang, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn
Journal: New England Journal of Medicine (2023)

Data regarding clinical outcomes after intravascular imaging–guided percutaneous coronary intervention (PCI) for complex coronary-artery lesions, as compared with outcomes after angiography-guided PCI, are limited. Download a PDF of the Research Summary. In this prospective, multicenter, open-label trial in South Korea, we randomly assigned patients with complex coronary-artery lesions in a 2:1 ratio to undergo either intravascular imaging–guided PCI or angiography-guided PCI. In the intravascular imaging group, the choice between intravascular ultrasonography and optical coherence tomography was at the operators' discretion. The primary end point was a composite of death from cardiac causes, target-vessel–related myocardial infarction, or clinically driven target-vessel revascularization. Safety was also assessed. A total of 1639 patients underwent randomization, with 1092 assigned to undergo intravascular imaging–guided PCI and 547 assigned to undergo angiography-guided PCI. At a median follow-up of 2.1 years (interquartile range, 1.4 to 3.0), a primary end-point event had occurred in 76 patients (cumulative incidence, 7.7%) in the intravascular imaging group and in 60 patients (cumulative incidence, 12.3%) in the angiography group (hazard ratio, 0.64; 95% confidence interval, 0.45 to 0.89; P=0.008). Death from cardiac causes occurred in 16 patients (cumulative incidence, 1.7%) in the intravascular imaging group and in 17 patients (cumulative incidence, 3.8%) in the angiography group; target-vessel–related myocardial infarction occurred in 38 (cumulative incidence, 3.7%) and 30 (cumulative incidence, 5.6%), respectively; and clinically driven target-vessel revascularization in 32 (cumulative incidence, 3.4%) and 25 (cumulative incidence, 5.5%), respectively. There were no apparent between-group differences in the incidence of procedure-related safety events. Among patients with complex coronary-artery lesions, intravascular imaging–guided PCI led to a lower risk of a composite of death from cardiac causes, target-vessel–related myocardial infarction, or clinically driven target-vessel revascularization than angiography-guided PCI. (Supported by Abbott Vascular and Boston Scientific; RENOVATE-COMPLEX-PCI ClinicalTrials.gov number, NCT03381872). QUICK TAKE VIDEO SUMMARYImaging- or Angiography-Guided PCI 02:11
mRNA delivery in cancer immunotherapy
Authors: Yichen Zhong, Shi Du, Yizhou Dong
Journal: Acta Pharmaceutica Sinica B (2023)

Messenger RNA (mRNA) has drawn much attention in the medical field. Through various treatment approaches including protein replacement therapies, gene editing, and cell engineering, mRNA is becoming a potential therapeutic strategy for cancers. However, delivery of mRNA into targeted organs and cells can be challenging due to the unstable nature of its naked form and the low cellular uptake. Therefore, in addition to mRNA modification, efforts have been devoted to developing nanoparticles for mRNA delivery. In this review, we introduce four categories of nanoparticle platform systems: lipid, polymer, lipid-polymer hybrid, and protein/peptide-mediated nanoparticles, together with their roles in facilitating mRNA-based cancer immunotherapies. We also highlight promising treatment regimens and their clinical translation.
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Authors: Arun J. Sanyal, Breda Munoz, Kenneth Cusi, A. Sidney Barritt, Mark Muthiah, Andrea R. Mospan, K. Rajender Reddy, Roberto Firpi-Morell, Paul J. Thuluvath, Kalyan Ram Bhamidimarri, Michael W. Fried, Manal Abdelmalek, Humberto Aguilar, Aijaz Ahmed, Alina Allen, Sarah Barlow, Sid Barritt, David Bernstein, Kaylan Bhamidimarri, Liana Billings, Kyle Brown, Robert Brown, Karen Corbin, Kenneth Cusi, Andrew deLemos, Karan Emerick, Roberto Firpi-Morell, Maged Adel Ghali, Zachary Henry, Whitney Jackson, Sujit Janardhan, Mohammad Kabbany, Nyingi Kemmer, David Koch, Justin Kupec, Charles Landis, Mary Katherine Lawrence, Cynthia Levy, Steven Lidofsky, Anna Lok, Velimir Luketic, Enrique Martinez, Craig McClain, Patrick McKiernan, Ellen Mitchell, Mazen Noureddin, Sirish Palle, Yen Pham, David Pound, Rajender Reddy, Fredric Regenstein, Mary Rinella, Fedja Rochling, Bryan Rudolph, Vinod Rustgi, Adnan Said, Niharika Samala, Souvik Sarkar, Kenneth Sherman, Mitchell Shiffman, Coleman Smith, Jawahar Taunk, Brent Tetri, Paul Thuluvath, Huy Trinh, Elizabeth Verna, Miriam Vos, L. Michael Weiss, Mark Wong, Kathleen Wyne, Stavra Xanthakos
Journal: Clinical Gastroenterology and Hepatology (2023)
Diffuse Esophageal Glycogenic Acanthosis: Not Always Incidental
Authors: Yasuhisa Jimbo, Makoto Furihata, Taro Osada
Journal: Clinical Gastroenterology and Hepatology (2023)

A 39-year-old man presented for workup of bloating. He had no relevant medical history. Colonoscopy showed a circumferential tumor in the transverse colon with biopsy specimens confirming adenocarcinoma (Figure A). Esophagogastroduodenoscopy showed diffuse glycogenic acanthosis (GA) throughout the esophagus, verified as glycogen-rich by iodine staining (Figure B). The patient was noted to have macrocephaly, mucocutaneous trichilemmomas (Figure C), and oral papillomas (Figure D). Macrocephaly and macroscopic manifestations met the major criteria of Cowden syndrome (CS), whereas colon cancer development and GA met the minor criteria. He underwent transverse colectomy with lymph node dissection. Despite adjuvant and salvage chemotherapy, he died after 16 months from peritoneal dissemination. Germline pathogenic variants of the PTEN gene cause phosphatase and tensine homolog hamartoma tumor syndrome (PHTS), including CS, Bannayan–Riley–Ruvalcaba syndrome, and phosphatase and tensine homolog-related Proteus syndrome. More than 80% of CS cases inherit PTEN mutations. The patient was diagnosed with CS based on germline PTEN mutation (CGA (arginine)→TGA (stop codon) at codon 130, exon 5. CS patients have a 30% lifetime malignancy risk. The patient had not been diagnosed with CS before because he had never undergone any medical check-up. GA is considered an incidental finding in most clinical settings; however, it should be noted that it also can be a PHTS-related gastrointestinal manifestation. In the appropriate context, the association of diffuse GA with PHTS should be kept in mind for early diagnosis and management. The authors would like to thank Editage (www.editage.com) for English language editing.
CC chemokines family in fibrosis and aging: From mechanisms to therapy
Authors: Wangrui Lei, Liyuan Jia, Zheng Wang, Zhenxing Liang, Aizhen Zhao, Yanqing Liu, Ye Tian, Lin Zhao, Yawu Chen, Guangyong Shi, Zhi Yang, Yang Yang, Xuezeng Xu
Journal: Ageing Research Reviews (2023)
Influence of Cardiac Remodeling on Clinical Outcomes in Patients With Aortic Regurgitation
Authors: Maan Malahfji, Valentina Crudo, Yodying Kaolawanich, Duc T. Nguyen, Amr Telmesani, Mujtaba Saeed, Michael J. Reardon, William A. Zoghbi, Venkateshwar Polsani, Michael Elliott, Robert O. Bonow, Edward A. Graviss, Raymond Kim, Dipan J. Shah
Journal: Journal of the American College of Cardiology (2023)
Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial
Authors: Roberto Diletti, Wijnand K den Dekker, Johan Bennett, Carl E Schotborgh, Rene van der Schaaf, Manel Sabaté, Raúl Moreno, Koen Ameloot, Rutger van Bommel, Daniele Forlani, Bert van Reet, Giovanni Esposito, Maurits T Dirksen, Willem P T Ruifrok, Bert R C Everaert, Carlos Van Mieghem, Jacob J Elscot, Paul Cummins, Mattie Lenzen, Salvatore Brugaletta, Eric Boersma, Nicolas M Van Mieghem
Journal: The Lancet (2023)
Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care
Authors: Amrita Mukhopadhyay, Harmony R. Reynolds, Lawrence M. Phillips, Arielle R. Nagler, William C. King, Adam Szerencsy, Archana Saxena, Rod Aminian, Nathan Klapheke, Leora I. Horwitz, Stuart D. Katz, Saul Blecker
Journal: Journal of the American College of Cardiology (2023)
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms
Authors: Elisabeth A. Larson, Maria Dalamaga, Faidon Magkos
Journal: Seminars in Cancer Biology (2023)

Cancer ranks among the five leading causes of death in almost all countries and has important repercussions for individual and public health, the healthcare system, and society in general. Obesity increases the incidence of many types of cancer, but growing evidence suggests that physical activity may decrease risk for developing a variety of obesity-related cancer types, and, in some cases, may improve cancer prognosis and mortality rates. This review summarizes recent evidence on the effect of physical activity on obesity-related cancer prevention and survival. For some cancers, including breast, colorectal, and endometrial cancer, there is strong evidence for a preventative effect of exercise, but for many others, including gallbladder and kidney cancer, and multiple myeloma, evidence is inconsistent or largely lacking. Though many potential mechanisms have been proposed to explain the onco-protective effect of exercise, including improved insulin sensitivity, alterations in sex hormone availability, improved immune function and inflammation, myokine secretion, and modulation of intracellular signaling at the level of AMP kinase, the exact mechanism(s) of action within each cancer subtype remains poorly defined. Overall, a deeper understanding of how exercise can help against cancer and of the exercise parameters that can be altered to optimize exercise prescription is necessary and should be the subject of future investigation.
Change in the psychological self in people living with dementia: A scoping review
Authors: Aikaterini Mentzou, Judith Sixsmith, Maggie P. Ellis, Josephine Ross
Journal: Clinical Psychology Review (2023)

Alterations in one's sense of self are often considered a significant psychological symptom of dementia. However, the self is not a unified construct; it consists of a set of closely connected, yet substantive, manifestations which might not be equally impacted by dementia. Recognising the multidimensional nature of the self, the current scoping review aimed to explore the nature and scope of the evidence demonstrating change in the psychological self in people living with dementia. Adopting a cognitive psychological framework, a hundred and five (105) quantitative and qualitative studies were reviewed, and findings were organised into three main types of self-manifestations: high-order manifestations, functional aspects of the self, and foundational manifestations. Overall, the results show that although there are alterations in some of these different manifestations of the self, these do not imply a global loss of selfhood. Despite notable cognitive changes during dementia, it seems that preserved aspects of self may be enough to compensate for potential weakening of some self-processes such as autobiographical recall. Better understanding alterations in selfhood is key to addressing psychological symptoms of people living with dementia, such as feelings of disconnection and reduced agency, and may inform new pathways for dementia care interventions.
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant
Authors: Bernhard Haring, Rebecca P. Hunt, Aladdin H. Shadyab, Charles Eaton, Robert Kaplan, Lisa Warsinger Martin, Gurusher Panjrath, Lewis H. Kuller, Themistocles Assimes, Charles Kooperberg, Sylvia Wassertheil-Smoller
Journal: JACC Heart Failure (2023)
Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus
Authors: François Chasset, Léa Jaume, Alexis Mathian, Noémie Abisror, Amélie Dutheil, Annick Barbaud, Diane Kottler, Céline Girard, Sandrine Jousse-Joulin, Marie Tauber, Cristina Bulai Livideanu, Véronique Avettand-Fenoel, Raphael Lhote, Micheline Pha, Zahir Amoura
Journal: Journal of the American Academy of Dermatology (2023)